São Paulo - Delayed Quote BRL

Raia Drogasil S.A. (RADL3.SA)

Compare
21.13
-0.22
(-1.03%)
At close: January 8 at 6:07:42 PM GMT-3
Loading Chart for RADL3.SA
DELL
  • Previous Close 21.35
  • Open 0.00
  • Bid 21.03 x --
  • Ask 21.19 x --
  • Day's Range 0.00 - 0.00
  • 52 Week Range 0.00 - 30.40
  • Volume 0
  • Avg. Volume 7,702,738
  • Market Cap (intraday) 36.243B
  • Beta (5Y Monthly) 0.31
  • PE Ratio (TTM) 32.02
  • EPS (TTM) 0.66
  • Earnings Date Mar 3, 2025 - Mar 7, 2025
  • Forward Dividend & Yield 0.29 (1.37%)
  • Ex-Dividend Date Dec 5, 2024
  • 1y Target Est 29.87

Raia Drogasil S.A. engages in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines in Brazil. It sells its products through stores, telesales, and call centers in the states of São Paulo, Tocantins, and Pernambuco. The company was founded in 1905 and is headquartered in São Paulo, Brazil.

rdsaude.com.br

62,402

Full Time Employees

December 31

Fiscal Year Ends

Recent News: RADL3.SA

View More

Performance Overview: RADL3.SA

Trailing total returns as of 1/8/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

RADL3.SA
3.95%
IBOVESPA
0.55%

1-Year Return

RADL3.SA
27.41%
IBOVESPA
9.39%

3-Year Return

RADL3.SA
6.03%
IBOVESPA
16.46%

5-Year Return

RADL3.SA
6.51%
IBOVESPA
2.54%

Compare To: RADL3.SA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: RADL3.SA

View More

Valuation Measures

As of 1/8/2025
  • Market Cap

    36.24B

  • Enterprise Value

    43.40B

  • Trailing P/E

    31.82

  • Forward P/E

    23.81

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.94

  • Price/Book (mrq)

    5.75

  • Enterprise Value/Revenue

    1.15

  • Enterprise Value/EBITDA

    13.77

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    2.94%

  • Return on Assets (ttm)

    7.12%

  • Return on Equity (ttm)

    18.81%

  • Revenue (ttm)

    37.7B

  • Net Income Avi to Common (ttm)

    1.11B

  • Diluted EPS (ttm)

    0.66

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    410.51M

  • Total Debt/Equity (mrq)

    119.84%

  • Levered Free Cash Flow (ttm)

    1.22B

Research Analysis: RADL3.SA

View More

People Also Watch